Thoratec gets study boost for new-generation heart pump
This article was originally published in Clinica
Executive Summary
Thoratec saw its share price jump last week, after a pivotal US trial of its HeartMate II device showed that the next-generation heart pump provided reliable, long-term support in patients awaiting a heart transplant, and improve their quality of life.